Abstracts

AAV-1, -8, and -9 Seroprevalence in Healthy Donors and People Living With HIV in Sub-Saharan Africa

Background: Adeno-associated virus (AAV)-vectored delivery of monoclonal (m) HIV-specific broadly (b) neutralizing (n) antibodies (Abs) holds promise for treating HIV infection. Because AAV is non-pathogenic and its genome persists in host cells, successful AAV/bnAb transduction of long-lived cells, such as myocytes, can result in continuous bnAb expression for years, possibly decades. We set out to…

Potent Cross-Reactive HIV-1 Neutralization in Fusion Peptide-Primed SHIV-Infected Macaques

Background: An effective antibody-based HIV-1 vaccine will require the consistent induction of potent cross-reactive HIV-1-neutralizing responses. Epitope-focusing approaches have elicited consistent, but low titer, cross-clade neutralizing responses against multiple sites of vulnerability. However, consistent, broad, and potent neutralizing responses against HIV-1 have not been achieved by vaccination. Methods: To demonstrate feasibility towards the consistent, broad,…

Enema Use Minimally Impacts Immunity and Does Not Affect Susceptibility to Low-Dose Intrarectal SIV

Background: Men who have sex with men (MSM) are disproportionately affected by HIV. Increased susceptibility to HIV in MSM is attributed to high frequencies of susceptible CD4+ T-cells, GI epithelial barrier disruption, and dysbiosis of the intestinal microbiome. Although colorectal epithelial barrier damage is due, in part, to inflammation resulting from receptive anal intercourse, rectal…

Suppressing Asymptomatic CMV With Letermovir Reshapes Cardiometabolic Proteome in Treated HIV

Background: People with HIV (PWH) and CMV have higher cardiometabolic disease risk than those without HIV despite antiretroviral therapy (ART), but mechanisms are unclear. Methods: We performed a randomized trial of letermovir (CMV terminase inhibitor, 480 mg daily) in ART-suppressed CMV-seropositive PWH to assess whether letermovir therapy for 48 weeks reduced plasma sTNFR2 levels (primary…

Cannabis Use Enhances Mucosal Immunity and the Microbiome in Individuals With HIV

Background: Cannabis is widely used by people living with HIV (PLWH) both recreationally and to mitigate HIV- or antiretroviral therapy (ART)-associated nausea, pain, anorexia, or other symptoms. Here, we evaluated immune function and intestinal health among a cohort of ART-treated, cannabis-using, and non-using PLWH. We hypothesized that cannabis using PLWH would have reduced inflammation and…